Ian Creese - Publications

Affiliations: 
Rutgers University, New Brunswick, New Brunswick, NJ, United States 
Area:
Psychopharmacology

158 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2001 Ouagazzal AM, Tepper JM, Creese I. Reducing gene expression in the brain via antisense methods. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 5.4. PMID 18428503 DOI: 10.1002/0471142301.ns0504s00  1
2000 Ouagazzal AM, Creese I. Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacology, Biochemistry, and Behavior. 67: 637-45. PMID 11164096 DOI: 10.1016/S0091-3057(00)00406-8  1
1999 Creese I. Rate processing constraints may underlie developmental language impairments and also hemispheric specialization for speech. Brain Research Bulletin. 50: 431-2. PMID 10643469 DOI: 10.1016/S0361-9230(99)00179-3  1
1999 Lee H, Tarazi FI, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sciences. 64: 1595-602. PMID 10328519 DOI: 10.1016/S0024-3205(99)00106-X  1
1998 Creese I, Tepper JM. Antisense knockdown of brain dopamine receptors. Advances in Pharmacology (San Diego, Calif.). 42: 517-20. PMID 9327954 DOI: 10.1016/S1054-3589(08)60803-0  1
1997 Dong ZJ, Chen LJ, Jin GZ, Creese I. GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum. Biochemical Pharmacology. 54: 227-32. PMID 9271326 DOI: 10.1016/S0006-2952(97)00152-4  1
1997 Zang Z, Creese I. Differential regulation of expression of rat hippocampal muscarinic receptor subtypes following fimbria-fornix lesion. Biochemical Pharmacology. 53: 1379-82. PMID 9214700 DOI: 10.1016/S0006-2952(97)00074-9  1
1997 Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 78: 985-96. PMID 9174067 DOI: 10.1016/S0306-4522(96)00631-8  1
1997 Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. The Journal of Pharmacology and Experimental Therapeutics. 280: 561-9. PMID 9023264  1
1997 Florijn WJ, Tarazi FI, Creese I. Chapter 4 Dopamine receptors Principles of Medical Biology. 8: 73-94. DOI: 10.1016/S1569-2582(97)80066-9  1
1996 Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. The Journal of Neuropsychiatry and Clinical Neurosciences. 8: 223-6. PMID 9081563  1
1996 Tarazi FI, Florijn WJ, Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128: 371-9. PMID 8986008 DOI: 10.1007/s002130050147  1
1995 Pothos EN, Creese I, Hoebel BG. Restricted eating with weight loss selectively decreases extracellular dopamine in the nucleus accumbens and alters dopamine response to amphetamine, morphine, and food intake. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 6640-50. PMID 7472425  1
1994 Koutouzis TK, Borlongan CV, Scorcia T, Creese I, Cahill DW, Freeman TB, Sanberg PR. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Research. 646: 242-6. PMID 8069670 DOI: 10.1016/0006-8993(94)90085-X  1
1994 Zang Z, Florijn W, Creese I. Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochemical Pharmacology. 48: 225-8. PMID 8053918 DOI: 10.1016/0006-2952(94)90090-6  1
1993 Zhang M, Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neuroscience Letters. 161: 223-6. PMID 7903803 DOI: 10.1016/0304-3940(93)90299-Z  1
1992 Xu SX, Monsma FJ, Sibley DR, Creese I. Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sciences. 50: 383-96. PMID 1732708 DOI: 10.1016/0024-3205(92)90440-Z  1
1992 Creese I, Sibley DR, Xu SX. Expression of rat striatal D1 and D2 dopamine receptor mRNAs: ontogenetic and pharmacological studies. Neurochemistry International. 20: 45S-48S. PMID 1365454 DOI: 10.1016/0197-0186(92)90209-A  1
1992 Kirch DG, Taylor TR, Creese I, Xu SX, Wyatt RJ. Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors. The Journal of Pharmacy and Pharmacology. 44: 89-92. PMID 1352822  1
1991 Tepper JM, Creese I, Schwartz DH. Stimulus-evoked changes in neostriatal dopamine levels in awake and anesthetized rats as measured by microdialysis. Brain Research. 559: 283-92. PMID 1794102 DOI: 10.1016/0006-8993(91)90013-L  1
1991 Xu SX, Hatada Y, Black LE, Creese I, Sibley DR. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. The Journal of Pharmacology and Experimental Therapeutics. 257: 608-15. PMID 1674530  1
1991 Creese I, Xu SX. Regulation of dopamine D2 receptors: molecular mechanisms European Neuropsychopharmacology. 1: 408-409.  1
1990 van Tol HH, Riva M, Civelli O, Creese I. Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA level. Neuroscience Letters. 111: 303-8. PMID 1970862 DOI: 10.1016/0304-3940(90)90279-I  1
1990 Creese I, Van Tol HHM, Riva M, Civelli O. Lack of effect of chromic dopamine receptor blockade on D2 dopamine receptor mRNA levels European Journal of Pharmacology. 183: 1404.  1
1989 Norman AB, Eubanks JH, Creese I. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain. The Journal of Pharmacology and Experimental Therapeutics. 248: 1116-22. PMID 2703964  1
1989 Riva MA, Creese I. Reevaluation of the regulation of beta-adrenergic receptor binding by desipramine treatment. Molecular Pharmacology. 36: 211-8. PMID 2546051  1
1989 Riva MA, Creese I. Comparison of two putatively selective radioligands for labeling central nervous system beta-adrenergic receptors: inadequacy of [3H]dihydroalprenolol. Molecular Pharmacology. 36: 201-10. PMID 2546050  1
1988 Hess EJ, Norman AB, Creese I. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 8: 2361-70. PMID 2907912  1
1988 Friedhoff AJ, Pickar D, Axelrod J, Creese I, Davis KL, Gallagher DW, Greengard P, Housman D, Maas JW, Richelson E. Neurochemistry and neuropharmacology. Schizophrenia Bulletin. 14: 399-412. PMID 2905525 DOI: 10.1093/schbul/14.3.399  1
1988 Battaglia G, Norman AB, Creese I. Age-related differential recovery rates of rat striatal D-1 dopamine receptors following irreversible inactivation. European Journal of Pharmacology. 145: 281-90. PMID 2895004 DOI: 10.1016/0014-2999(88)90431-1  1
1987 Hess EJ, Battaglia G, Norman AB, Creese I. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro. Molecular Pharmacology. 31: 50-7. PMID 3100940  1
1987 Koob GF, Le HT, Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neuroscience Letters. 79: 315-20. PMID 2958724 DOI: 10.1016/0304-3940(87)90451-4  1
1987 Norman AB, Battaglia G, Creese I. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 7: 1484-91. PMID 2952771  1
1987 Hess EJ, Bracha HS, Kleinman JE, Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sciences. 40: 1487-97. PMID 2951573 DOI: 10.1016/0024-3205(87)90381-X  1
1987 Battaglia G, Norman AB, Creese I. Differential serotonin2 receptor recovery in mature and senescent rat brain after irreversible receptor modification: effect of chronic reserpine treatment. The Journal of Pharmacology and Experimental Therapeutics. 243: 69-75. PMID 2889827  1
1986 Norman AB, Battaglia G, Creese I. Regulation of putative muscarinic cholinergic receptor subtypes in rat brain. Neurochemistry International. 9: 337-47. PMID 20493134 DOI: 10.1016/0197-0186(86)90071-9  1
1986 Morrow AL, Chen AD, Creese I. Modulation of alpha-1 adrenergic receptors in rat brain following chronic reserpine. Neurochemistry International. 8: 243-7. PMID 20493053 DOI: 10.1016/0197-0186(86)90170-1  1
1986 Norman AB, Blaker SN, Thal L, Creese I. Effects of aging and cholinergic deafferentation on putative muscarinic cholinergic receptor subtypes in rat cerebral cortex. Neuroscience Letters. 70: 289-94. PMID 3774231 DOI: 10.1016/0304-3940(86)90479-9  1
1986 Norman AB, Creese I. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain. Molecular Pharmacology. 30: 96-103. PMID 3755499  1
1986 Hess EJ, Albers LJ, Le H, Creese I. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. The Journal of Pharmacology and Experimental Therapeutics. 238: 846-54. PMID 3018223  1
1986 Morrow AL, Creese I. Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. Molecular Pharmacology. 29: 321-30. PMID 3010073  1
1986 Battaglia G, Norman AB, Hess EJ, Creese I. Forskolin potentiates the stimulation of rat striatal adenylate cyclase mediated by D-1 dopamine receptors, guanine nucleotides, and sodium fluoride. Journal of Neurochemistry. 46: 1180-5. PMID 3005508 DOI: 10.1111/j.1471-4159.1986.tb00635.x  1
1986 Amalric M, Koob GF, Creese I, Swerdlow NR. "Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat. Life Sciences. 39: 1985-93. PMID 2946915 DOI: 10.1016/0024-3205(86)90322-X  1
1986 Battaglia G, Norman AB, Hess EJ, Creese I. Functional recovery of D1 dopamine receptor-mediated stimulation of rat striatal adenylate cyclase activity following irreversible receptor modification by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): evidence for spare receptors. Neuroscience Letters. 69: 290-5. PMID 2945128  1
1986 Battaglia G, Norman AB, Newton PL, Creese I. In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery. Journal of Neurochemistry. 46: 589-93. PMID 2934516  1
1986 Creese I, Hess EJ. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia. Clinical Neuropharmacology. 9: 14-6. PMID 2882838  1
1986 Hess EJ, Creese I. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390. Psychopharmacology Bulletin. 22: 605-12. PMID 2879304  1
1986 Hess EJ, Creese I. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390. Advances in Experimental Medicine and Biology. 204: 29-52. PMID 2878579  1
1986 Hess EJ, Battaglia G, Norman AB, Iorio LC, Creese I. Guanine nucleotide regulation of agonist interactions at [3H]SCH23390-labeled D1 dopamine receptors in rat striatum. European Journal of Pharmacology. 121: 31-8. PMID 2869957 DOI: 10.1016/0014-2999(86)90389-4  1
1985 Morrow AL, Norman AB, Battaglia G, Loy R, Creese I. Up-regulation of serotonergic binding sites labeled by [3H]WB4101 following fimbrial transection and 5,7-dihydroxytryptamine-induced lesions. Life Sciences. 37: 1913-22. PMID 4058260 DOI: 10.1016/0024-3205(85)90009-8  1
1985 Morrow AL, Loy R, Creese I. Alteration of nicotinic cholinergic agonist binding sites in hippocampus after fimbria transection. Brain Research. 334: 309-14. PMID 3995322 DOI: 10.1016/0006-8993(85)90223-9  1
1985 Leff SE, Creese I. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor. Molecular Pharmacology. 27: 184-92. PMID 3969067  1
1985 Leff SE, Hamblin MW, Creese I. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states. Molecular Pharmacology. 27: 171-83. PMID 3969066  1
1985 Morrow AL, Battaglia G, Norman AB, Creese I. Identification of subtypes of [3H]prazosin-labelled alpha 1 receptor binding sites in rat brain. European Journal of Pharmacology. 109: 285-7. PMID 2987000 DOI: 10.1016/0014-2999(85)90432-7  1
1985 Battaglia G, Norman AB, Hess EJ, Creese I. D2 dopamine receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in rat striatum. Neuroscience Letters. 59: 177-82. PMID 2932659 DOI: 10.1016/0304-3940(85)90196-X  1
1985 Norman AB, Battaglia G, Creese I. [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity. Molecular Pharmacology. 28: 487-94. PMID 2867462  1
1985 Creese I, Chen A. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. European Journal of Pharmacology. 109: 127-8. PMID 2859993 DOI: 10.1016/0014-2999(85)90549-7  1
1985 Norman AB, Battaglia G, Creese I. Properties of 3H-WB4101-labeled 5HT-1 receptors in rat brain Federation Proceedings. 44: No. 4814.  1
1985 Battaglia G, Norman AB, Creese I. Forskolin effects on the stimulatory and inhibitory components of rat striatal adenylate cyclase Federation Proceedings. 44: No. 574.  1
1984 Leff SE, Chen A, Creese I. Sulpiride isomers exhibit reversed stereospecificity for D-1 and D-2 dopamine receptors in the CNS. Neuropharmacology. 23: 589-90. PMID 6738827 DOI: 10.1016/0028-3908(84)90034-0  1
1984 Hamblin MW, Leff SE, Creese I. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochemical Pharmacology. 33: 877-87. PMID 6712712 DOI: 10.1016/0006-2952(84)90441-6  1
1984 Leff SE, Gariano R, Creese I. Dopamine receptor turnover rates in rat striatum are age-dependent. Proceedings of the National Academy of Sciences of the United States of America. 81: 3910-4. PMID 6587399  1
1984 Creese I, Sibley DR, Leff SE. Agonist interactions with dopamine receptors: focus on radioligand-binding studies. Federation Proceedings. 43: 2779-84. PMID 6383871  1
1984 Norman AB, Battaglia G, Morrow AL, Creese I. [3H]WB4101 labels S1 serotonin receptors in rat cerebral cortex. European Journal of Pharmacology. 106: 461-2. PMID 6152223 DOI: 10.1016/0014-2999(84)90743-X  1
1983 Loy R, Morrow AL, Creese I. Cholinergic denervation induces adrenergic receptor increases: correlation with sympathetic axon sprouting in hippocampus. Birth Defects Original Article Series. 19: 409-15. PMID 6871408  1
1983 Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Molecular Pharmacology. 23: 295-302. PMID 6835198  1
1983 Sibley DR, Creese I. Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. The Journal of Biological Chemistry. 258: 4957-65. PMID 6833284  1
1983 Leff SE, Creese I. Dopaminergic D-3 binding sites are not presynaptic autoreceptors. Nature. 306: 586-9. PMID 6417548  1
1983 Creese I, Sibley DR, Leff S. Classification of dopamine receptors. Advances in Biochemical Psychopharmacology. 37: 255-66. PMID 6416028  1
1983 Creese I, Sibley DR, Hamblin MW, Leff SE. Dopamine receptors in the central nervous system. Advances in Biochemical Psychopharmacology. 36: 125-34. PMID 6344562 DOI: 10.1016/B978-008055232-3.60151-5  0.8
1983 Morrow AL, Loy R, Creese I. Septal deafferentation increases hippocampal adrenergic receptors: correlation with sympathetic axon sprouting. Proceedings of the National Academy of Sciences of the United States of America. 80: 6718-22. PMID 6314338  1
1983 Sibley DR, Creese I. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Molecular Pharmacology. 23: 585-93. PMID 6223205  1
1983 Creese I, Sibley DR, Hamblin MW, Leff SE. The classification of dopamine receptors: relationship to radioligand binding. Annual Review of Neuroscience. 6: 43-71. PMID 6220666 DOI: 10.1146/annurev.ne.06.030183.000355  1
1983 Hamblin MW, Creese I. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sciences. 32: 2247-55. PMID 6133202 DOI: 10.1016/0024-3205(83)90423-X  1
1983 Creese I. Classical and atypical antipsychotic drugs: new insights Trends in Neurosciences. 6: 479-481. DOI: 10.1016/0166-2236(83)90229-1  1
1983 Creese I. Dopamine receptors explained | DIE DOPAMIN-REZEPTOREN Nervenheilkunde. 2: 88-93. DOI: 10.1016/0166-2236(82)90019-4  1
1983 Leff SE, Creese I. Dopamine receptors re-explained Trends in Pharmacological Sciences. 4: 463-467. DOI: 10.1016/0165-6147(83)90494-7  1
1983 Creese I, Morrow AL, Hamblin MW, Leff SE, Sibley DR. Radioligand binding studies of dopamine receptors in the central nervous system Advances in the Biosciences. 44: 1-50.  1
1982 Leff SE, Creese I. Solubilization of D-2 dopamine receptors from canine caudate: agonist-occupation stabilizes guanine nucleotide sensitive receptor complexes. Biochemical and Biophysical Research Communications. 108: 1150-7. PMID 7181887 DOI: 10.1016/0006-291X(82)92121-0  1
1982 Hamblin MW, Creese I. Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranes. Molecular Pharmacology. 21: 52-6. PMID 7132962  1
1982 Creese I, Leff SE. Dopamine receptors: a classification. Journal of Clinical Psychopharmacology. 2: 329-35. PMID 7130434  0.52
1982 Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B. High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biological Psychiatry. 17: 849-52. PMID 7115836  0.32
1982 Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Synder SH. Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry. 39: 991-7. PMID 7115016 DOI: 10.1001/archpsyc.1982.04290090001001  1
1982 Hamblin MW, Creese I. 3H-dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodium. Life Sciences. 30: 1587-95. PMID 7078356 DOI: 10.1016/0024-3205(82)90248-X  1
1982 Sibley DR, Weinberger S, Segal DS, Creese I. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding. Experientia. 38: 1224-5. PMID 6890464 DOI: 10.1007/BF01959753  1
1982 Creese I, Morrow AL, Leff SE, Sibley DR, Hamblin MW. Dopamine receptors in the central nervous system. International Review of Neurobiology. 23: 255-301. PMID 6749737  1
1982 Creese I, Kuczenski R, Segal D. Lack of behavioral evidence for dopamine autoreceptor subsensitivity after acute electroconvulsive shock. Pharmacology, Biochemistry, and Behavior. 17: 375-6. PMID 6291070 DOI: 10.1016/0091-3057(82)90096-X  1
1982 Sibley DR, De Lean A, Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. The Journal of Biological Chemistry. 257: 6351-61. PMID 6176582  1
1982 Hamblin MW, Creese I. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes. Molecular Pharmacology. 21: 44-51. PMID 6127621  1
1982 Sibley DR, Leff SE, Creese I. Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sciences. 31: 637-45. PMID 6127585 DOI: 10.1016/0024-3205(82)90764-0  1
1982 Creese I, Sibley DR. Comments on the commentary by Dr. Seeman Biochemical Pharmacology. 31: 2568-2569. DOI: 10.1016/0006-2952(82)90701-8  1
1982 Leff SE, Creese I. Solubilization of a guanine nucleotide sensitive form of the D-2 dopamine receptor from brain requires agonist occupancy Federation Proceedings. 41: No. 7968.  1
1981 Leff S, Sibley DR, Hamblin M, Creese I. Ascorbic acid enables reversible dopamine receptor 3H-agonist binding. Life Sciences. 29: 2081-90. PMID 7311734 DOI: 10.1016/0024-3205(81)90665-2  1
1981 Leff S, Adams L, Hyttel J, Creese I. Kainate lesion dissociates striatal dopamine receptor radioligand binding sites. European Journal of Pharmacology. 70: 71-5. PMID 7215442 DOI: 10.1016/0014-2999(81)90434-9  1
1981 Creese I, Sibley DR, Leff S, Hamblin M. Dopamine receptors: subtypes, localization and regulation. Federation Proceedings. 40: 147-52. PMID 7007083  1
1981 Meltzer HY, Busch DA, Creese IR, Snyder SH, Fang VS. Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls. Psychiatry Research. 5: 95-105. PMID 6944710 DOI: 10.1016/0165-1781(81)90065-2  0.32
1981 Creese I, Sibley DR. Receptor adaptations to centrally acting drugs. Annual Review of Pharmacology and Toxicology. 21: 357-91. PMID 6263174 DOI: 10.1146/annurev.pa.21.040181.002041  1
1981 Sanberg PR, Creese I. Dopamine receptor stimulation and striatal kainic acid neurotoxicity. The Journal of Pharmacy and Pharmacology. 33: 674-5. PMID 6117626  1
1981 Tune LE, Creese I, DePaulo JR, Slavney PR, Snyder SH. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. The Journal of Nervous and Mental Disease. 169: 60-3. PMID 6108981  1
1981 Hamblin M, Creese I. Receptor binding and the discovery of psychotherapeutic drugs Drug Development Research. 1: 343-372.  1
1980 Sibley DR, Creese I. Dopamine receptor binding in bovine intermediate lobe pituitary membranes. Endocrinology. 107: 1405-9. PMID 7428676 DOI: 10.1210/endo-107-5-1405  0.96
1980 Mackay AV, Bird ED, Iversen LL, Spokes EG, Creese I, Snyder SH. Dopaminergic abnormalities in postmortem schizophrenic brain. Advances in Biochemical Psychopharmacology. 24: 325-33. PMID 7405668  1
1980 Sibley DR, Creese I. Pseudo non-competitive agonist interactions with dopamine receptors. European Journal of Pharmacology. 65: 131-3. PMID 7398773  1
1980 Hamblin M, Creese I. Phenoxybenzamine discriminates multiple dopamine receptors. European Journal of Pharmacology. 65: 119-21. PMID 7398772  1
1980 Usdin TB, Creese I, Snyder SH. Regulation by cations of [3H]spiroperidol binding associated with dopamine receptors of rat brain. Journal of Neurochemistry. 34: 669-76. PMID 6766497  1
1980 Mackay AV, Bird ED, Spokes EG, Rossor M, Iversen LL, Creese I, Snyder SH. Dopamine receptors and schizophrenia: drug effect or illness? Lancet. 2: 915-6. PMID 6107564 DOI: 10.1016/S0140-6736(80)92072-3  1
1980 Creese I, Snyder SH. Chronic neuroleptic treatment and dopamine receptor regulation. Advances in Biochemical Psychopharmacology. 24: 89-94. PMID 6105809  1
1980 Creese I. Central nervous system dopamine receptors. Advances in Biochemical Psychopharmacology. 21: 235-42. PMID 6103649  1
1980 Burnett GB, Prange AJ, Wilson IC, Jolliff LA, Creese IC, Synder SH. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology. 6: 109-20. PMID 6101910 DOI: 10.1159/000117742  0.52
1980 Tune LE, Creese I, Depaulo JR, Slavney PR, Coyle JT, Snyder SH. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. The American Journal of Psychiatry. 137: 187-90. PMID 6101524  1
1980 Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH. Low neuroleptic serum levels in patients receiving fluphenazine decanoate. The American Journal of Psychiatry. 137: 80-2. PMID 6101523  1
1979 Creese I, Sibley DR. Radioligand binding studies: evidence for multiple dopamine receptors. Communications in Psychopharmacology. 3: 385-95. PMID 546587  1
1979 Creese I, Stewart K, Snyder SH. Species variation in dopamine receptor binding. European Journal of Pharmacology. 60: 55-66. PMID 520417 DOI: 10.1016/0014-2999(79)90052-9  1
1979 Creese I, Usdin TB, Snyder SH. Dopamine receptor binding regulated by guanine nucleotides. Molecular Pharmacology. 16: 69-76. PMID 481426  1
1979 Creese I, Padgett L, Fazzini E, Lopez F. 3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors. European Journal of Pharmacology. 56: 411-2. PMID 477735 DOI: 10.1016/0014-2999(79)90274-7  1
1979 Sibley DR, Creese I. Guanine nucleotides regulate anterior pituitary dopamine receptors. European Journal of Pharmacology. 55: 341-3. PMID 456433 DOI: 10.1016/0014-2999(79)90207-3  1
1979 Creese I, Usdin T, Snyder SH. Guanine nucleotides distinguish between two dopamine receptors. Nature. 278: 577-8. PMID 431724 DOI: 10.1038/278577a0  1
1979 Snyder SH, Childers SR, Creese I. Molecular actions of opiates: historical overview and new findings on opiate receptor interactions with enkephalins and guanyl nucleotides. Advances in Biochemical Psychopharmacology. 20: 543-52. PMID 224663  1
1979 Childers SR, Creese I, Snowman AM, Synder SH. Opiate receptor binding affected differentially by opiates and opioid peptides. European Journal of Pharmacology. 55: 11-8. PMID 220062 DOI: 10.1016/0014-2999(79)90142-0  1
1979 Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH. Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations. Psychiatry Research. 1: 39-44. PMID 45128 DOI: 10.1016/0165-1781(79)90026-X  1
1979 Freedberg KA, Innis RB, Creese I, Snyder SH. Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sciences. 24: 2467-73. PMID 39211 DOI: 10.1016/0024-3205(79)90457-0  1
1979 Creese I, Snyder SH. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding. European Journal of Pharmacology. 56: 277-81. PMID 38973 DOI: 10.1016/0014-2999(79)90184-5  1
1978 Creese I, Snyder SH. Dopamine receptor binding of 3H-ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) regulated by guanyl nucleotides. European Journal of Pharmacology. 50: 459-61. PMID 699970 DOI: 10.1016/0014-2999(78)90156-5  1
1978 Creese I, Prosser T, Synder SH. Dopamine receptor binding: specificity, localization and regulation by ions and guanyl nucleotides. Life Sciences. 23: 495-9. PMID 692273 DOI: 10.1016/0024-3205(78)90160-1  1
1978 Thal L, Creese I, Snyder SH. 3H-Apomorphine interactions with dopamine receptors in calf brain. European Journal of Pharmacology. 49: 295-9. PMID 658143 DOI: 10.1016/0014-2999(78)90105-X  1
1978 Creese I, Snyder SH. 3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. European Journal of Pharmacology. 49: 201-2. PMID 658137 DOI: 10.1016/0014-2999(78)90080-8  1
1978 Creese I, Manian AA, Prosser TD, Snyder SH. 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: influence of chlorpromazine metabolites and derivatives. European Journal of Pharmacology. 47: 291-6. PMID 631182 DOI: 10.1016/0014-2999(78)90236-4  1
1978 Schwarcz R, Creese I, Coyle JT, Snyder SH. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature. 271: 766-8. PMID 625348 DOI: 10.1038/27766a0  1
1978 Creese I. Receptor binding: a tool to aid in determining the role of peptides in behavior. Neurosciences Research Program Bulletin. 16: 498-509. PMID 220553  1
1977 Creese I, Snyder SH. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature. 270: 180-2. PMID 927531 DOI: 10.1038/270180a0  1
1977 Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science (New York, N.Y.). 197: 596-8. PMID 877576  1
1977 Pardo JV, Creese I, Burt DR, Snyder SH. Ontogenesis of dopamine receptor binding in the corpus striatum of the rat. Brain Research. 125: 376-82. PMID 851885 DOI: 10.1016/0006-8993(77)90633-3  1
1977 Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science (New York, N.Y.). 196: 326-8. PMID 847477  1
1977 Creese I, Schneider R, Snyder SH. 3H-Spiroperidol labels dopamine receptors in pituitary and brain. European Journal of Pharmacology. 46: 377-81. PMID 590345 DOI: 10.1016/0014-2999(77)90232-1  1
1977 Enna SJ, Bennett JP, Bylund DB, Creese I, Burt DR, Charness ME, Yamamura HI, Simantov R, Snyder SH. Neurotransmitter receptor binding: regional distribution in human brain. Journal of Neurochemistry. 28: 233-6. PMID 13155 DOI: 10.1111/j.1471-4159.1977.tb07733.x  1
1977 Enna SJ, Bennett JP, Burt DR, Creese I, U'Prichard DC, Greenberg DA, Snyder SH. Stereospecificity and clinical potency of neuroleptics (reply) Nature. 267: 184. DOI: 10.1038/267184a0  1
1977 Creese I, Snyder SH. Chapter 25. Brain Neurotransmitter Receptor Binding and Neuroleptic Drugs Annual Reports in Medicinal Chemistry. 12: 249-259. DOI: 10.1016/S0065-7743(08)60310-3  1
1976 Creese I, Burt DR, Snyder SH. Dopamine receptors and average clinical doses. Science (New York, N.Y.). 194: 546. PMID 17783671 DOI: 10.1126/science.194.4264.546  1
1976 Creese I, Feinberg AP, Snyder SH. Butyrophenone influences on the opiate receptor. European Journal of Pharmacology. 36: 231-5. PMID 1261596 DOI: 10.1016/0014-2999(76)90277-6  1
1976 Burt DR, Creese I, Snyder SH. Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Molecular Pharmacology. 12: 800-12. PMID 995128  1
1976 Burt DR, Creese I, Snyder SH. Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Molecular Pharmacology. 12: 631-8. PMID 958211  1
1976 Feinberg AP, Creese I, Snyder SH. The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists. Proceedings of the National Academy of Sciences of the United States of America. 73: 4215-9. PMID 186791 DOI: 10.1073/pnas.73.11.4215  1
1976 Enna SJ, Bennett JP, Burt DR, Creese I, Snyder SH. Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature. 263: 338-41. PMID 8733 DOI: 10.1038/263338a0  1
1976 Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (New York, N.Y.). 192: 481-3. PMID 3854  1
1976 Burt DR, Creese I, Snyder SH. Dopamine receptor binding of multiple ligands Trans.Amer.Soc.Neurochem.. 7: no. 228.  1
1975 Snyder SH, Creese I, Burt DR. The brain's dopamine receptor: labeling with (3H) dopamine and (3H) haloperidol. Psychopharmacology Communications. 1: 663-73. PMID 1241457  1
1975 Creese I, Burt DR, Synder SH. The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. Life Sciences. 17: 1715-9. PMID 1207384 DOI: 10.1016/0024-3205(75)90118-6  1
1975 Creese I, Iversen SD. Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity? Psychopharmacology Bulletin. 11: 12-3. PMID 1197588  1
1975 Creese I, Burt DR, Snyder SH. Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Sciences. 17: 933-1001. PMID 1195989 DOI: 10.1016/0024-3205(75)90454-3  1
1975 Iversen SD, Creese I. Behavioral correlates of dopaminergic supersensitivity. Advances in Neurology. 9: 81-92. PMID 1170717  1
1975 Creese I, Pasternak GW, Pert CB, Snyder SH. Discrimination by temperature of opiate agonist and antagonist receptor binding. Life Sciences. 16: 1837-42. PMID 1152613 DOI: 10.1016/0024-3205(75)90287-8  1
1975 Burt DR, Enna SJ, Creese I, Snyder SH. Dopamine receptor binding in the corpus striatum of mammalian brain. Proceedings of the National Academy of Sciences of the United States of America. 72: 4655-9. PMID 1060143  1
1975 Creese I, Snyder SH. Receptor binding and pharmacological activity of opiates in the guinea-pig intestine. The Journal of Pharmacology and Experimental Therapeutics. 194: 205-19. PMID 239219  1
1975 Creese I, Iversen SD. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Research. 83: 419-36. PMID 234270 DOI: 10.1016/0006-8993(75)90834-3  1
1974 Creese I, Iversen SD. The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat. Psychopharmacologia. 39: 345-57. PMID 4615333 DOI: 10.1007/BF00422974  1
1974 Creese I. Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. European Journal of Pharmacology. 28: 55-8. PMID 4473347 DOI: 10.1016/0014-2999(74)90111-3  1
1973 Creese I, Iversen SD. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Research. 55: 369-82. PMID 4145950 DOI: 10.1016/0006-8993(73)90302-8  1
1972 Creese I, Iversen SD. Amphetamine response in rat after dopamine neurone destruction. Nature: New Biology. 238: 247-8. PMID 4404010  1
Show low-probability matches.